The research has not yet yielded an aptamer that would most effectively and most specifically recognize staph. In his year-long investigation, Dobler tested about 80 samples among the thousands that may yield results.
He is writing up his research, and will present his findings in his masters thesis in December. Bohach, Maki and their teams hope to find funding to continue the study.
A good example of capture molecules are those that attach themselves to the toxins that staph makes, Bohach explained. We hope to identify particularly those toxins that are associated with the more virulent strains, including MRSA strains. Theres quite a bit known about the toxins, and we can in a limited number of steps screen and isolate staph for many different toxins at the same time.
So if youre looking specifically for MRSA, you could look for those bacterial molecules that are associated with it, and through that unique association, identify it with precision, he said.
As the research progresses, capture molecules for a variety of identifying toxins will be incorporated onto the biosensor, which will quickly read and accurately translate the toxin profile.
Using staph Pathogenesis as a Treatment Delivery System
Bohach and others members of his team also are looking at the mechanisms staph bacteria employ to enter host cells and proliferate.
Using nanowires and other nanomaterials (NMs), they aim to hijack the methods bacteria use for toxin delivery, and use them to deliver drug therapies specifically to infected cells.
Bohach is working with University of Idaho professor of physics and materials engineer David McIlroy, microbiologist Carolyn Hovde and others to develop nanowires and other nanomaterials (NMs) for use as innovative drug delivery systems.
McIlroy leads a team of seven researchers supported by the universitys Blue Ribbon Strategic Initiative funding. Their goal is to integrat
|Contact: Joni Kirk|
University of Idaho